Document:

<PAGE>

                                                          Exhibit 10.8

THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN
QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA
AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF
THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS
THE SALE OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102
OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO
THIS WARRANT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING
OBTAINED, UNLESS THE SALE IS SO EXEMPT.

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE
NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"),
OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES ARE SUBJECT
TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR
RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES
LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS SHOULD BE
AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS
INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES
MAY REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE
ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE
WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

            WARRANT TO PURCHASE SERIES E CONVERTIBLE PREFERRED STOCK

                                       OF

                           CIPHERGEN BIOSYSTEMS, INC.

                          VOID AFTER FEBRUARY 28, 2005

         This certifies that, for value received, SG Cowen Securities
Corporation or its permitted registered assigns ("REGISTERED HOLDER"), is
entitled, subject to the terms and conditions of this Warrant, at any time
before 5:00 p.m. Pacific Time on February 28, 2005, unless terminated earlier
under Section 11 hereof (the "EXPIRATION DATE") to purchase from Ciphergen
Biosystems, Inc., a California corporation (the "COMPANY"), up to One Hundred
Forty Six Thousand Six Hundred Thirty Five (146,635) shares of the Company's
Series E Convertible Preferred Stock, no par value per share (the "WARRANT
STOCK"), as constituted on March 8, 2000 (the "ISSUE DATE"), at the price of
Two Dollars Seventy Five cents ($2.75) per share (the "PURCHASE PRICE") upon
surrender of this Warrant at the principal office of the Company, together
with a duly executed subscription in the form attached hereto as EXHIBIT 1
and simultaneous payment of the full Purchase Price therefor in lawful money
of the United States as provided herein. The Purchase Price and the number
and character of shares of Warrant Stock purchasable hereunder are subject to
adjustment as provided herein. Unless the context otherwise requires, the
term "Warrant Stock" shall mean and include the stock and other securities
and property at any time receivable

<PAGE>

or issuable upon exercise of this Warrant. The term "Warrant" as used herein,
shall include this Warrant and any warrants delivered in substitution or
exchange therefor as provided herein.

         1.       EXERCISE.

                  1.1        METHOD OF EXERCISE. Subject to the terms and
conditions of this Warrant, the Registered Holder may exercise this Warrant
in whole or in part, at any time or from time to time, on any business day
prior to the Expiration Date by surrendering this Warrant at the principal
executive office of the Company, together with the subscription form attached
hereto duly executed by the Registered Holder and payment in full of the
Purchase Price or adjusted Purchase Price therefor, if applicable (as
determined in accordance with the terms hereof) for the number of shares of
Warrant Stock to be purchased upon such exercise of this Warrant.

                  1.2        FORM OF PAYMENT. Payment may be made by (i) a
check payable to the Company's order, (ii) wire transfer of funds to the
Company, (iii) cancellation of indebtedness of the Company to the Holder, or
(iv) any combination of the foregoing.

                  1.3        PARTIAL EXERCISE. Upon a partial exercise of
this Warrant: (i) the Purchase Amount immediately prior to such exercise
shall be reduced by the aggregate amount paid to the Company upon such
exercise of this Warrant, and (ii) this Warrant shall be surrendered by the
Registered Holder and replaced with a new Warrant of like tenor for purchase
of the number of remaining shares of Warrant Stock not previously purchased
shall be issued by the Company to the Registered Holder.

                  1.4        NO FRACTIONAL SHARES. No fractional shares may
be issued upon any exercise of this Warrant, and any fractions shall be
rounded down to the nearest whole number of shares. If upon any exercise of
this Warrant a fraction of a share results, the Company will pay the cash
value of any such fractional share, calculated on the basis of the Warrant
Price.

                  1.5        RESTRICTIONS ON EXERCISE. This Warrant may not
be exercised if the issuance of the Warrant Stock upon such exercise would
constitute a violation of any applicable federal or state securities laws or
other laws or regulations. As a condition to the exercise of this Warrant,
the Registered Holder shall execute the subscription form attached hereto.

                  1.6        NET EXERCISE ELECTION. The Registered Holder may
elect to convert all or a portion of this Warrant, without the payment by the
Registered Holder of any additional consideration, by the surrender of this
Warrant or such portion to the Company, with the net exercise election
selected in the subscription form attached hereto duly executed by the
Holder, into up to the number of shares of Warrant Stock that is obtained
under the following formula:

                               X = Y (A-B)
                                   -------
                                       A

                                       2

<PAGE>

where             X = the number of shares of Warrant Stock to be issued
                  to the Registered Holder pursuant to this Section 1.6.

                  Y = the Maximum Purchase Amount divided by the Warrant
                  Price.

                  A = the fair market value of one share of Warrant Stock, as
                  determined in good faith by the Company's Board of
                  Directors, as at the time the net exercise election is made
                  pursuant to this Section 1.6.

                  B = the Warrant Price.

                  The Company will promptly respond in writing to an inquiry
by the Registered Holder as to the then current fair market value of one
share of Warrant Stock.

         2.        VALID ISSUANCE. All shares of Warrant Stock issued upon
the exercise of this Warrant shall be validly issued, fully paid and
non-assessable. The Company shall not be required to pay any tax or other
charge imposed in connection with any transfer involved in the issue of any
certificate for shares of Warrant Stock, or any Common Stock or other
securities issuable upon conversion of such Warrant Stock ("CONVERSION
STOCK"), in any name other than that of the Registered Holder of this
Warrant, and in such case the Company shall not be required to issue or
deliver any stock certificate or security until such tax or other charge has
been paid, or it has been established to the Company's satisfaction that no
tax or other charge is due.

         3.        TRANSFER AND EXCHANGE. This Warrant and the rights
hereunder may not be transferred in whole or in part without the Company's
prior written consent and may not be transferred unless such transfer
complies with all applicable securities laws and the provisions of Section
10. If a transfer of all or part of this Warrant is permitted by the
preceding sentence, then this Warrant and all rights hereunder may be
transferred, in whole or in part, on the books of the Company maintained for
such purpose at the principal office of the Company referred to above, by the
Registered Holder hereof in person, or by duly authorized attorney, upon
surrender of this Warrant properly endorsed and upon payment of any necessary
transfer tax or other governmental charge imposed upon such transfer. Upon
any permitted partial transfer, the Company will issue and deliver to the
Registered Holder a new Warrant or Warrants with respect to the shares of
Warrant Stock not so transferred. Each taker and holder of this Warrant, by
taking or holding the same, consents and agrees that when this Warrant shall
have been so endorsed, the person in possession of this Warrant may be
treated by the Company, and all other persons dealing with this Warrant, as
the absolute owner hereof for any purpose and as the person entitled to
exercise the rights represented hereby, any notice to the contrary
notwithstanding; PROVIDED, HOWEVER that until a transfer of this Warrant is
duly registered on the books of the Company, the Company may treat the
Registered Holder hereof as the owner of this Warrant for all purposes.

         4.        ADJUSTMENT OF PURCHASE PRICE AND NUMBER OF SHARES. The
number and character of shares of Warrant Stock issuable upon exercise of
this Warrant (or any shares of

                                       3
<PAGE>

stock or other securities or property at the time receivable or issuable upon
exercise of this Warrant) and the Purchase Price therefor, are subject to
adjustment upon occurrence of the following events:

                  4.1        ADJUSTMENT FOR STOCK SPLITS, STOCK DIVIDENDS,
RECAPITALIZATIONS, ETC. The Purchase Price of this Warrant and the number of
shares of Warrant Stock issuable upon exercise of this Warrant shall each be
proportionally adjusted to reflect any stock dividend, stock split, reverse
stock split, combination of shares, reclassification, recapitalization or
other similar event altering the number of outstanding shares of Warrant
Stock.

                  4.2        ADJUSTMENT FOR OTHER DIVIDENDS AND
DISTRIBUTIONS. In case the Company shall make or issue, or shall fix a record
date for the determination of eligible holders entitled to receive, a
dividend or other distribution with respect to the Warrant Stock payable in
securities of the Company then, and in each such case, the Registered Holder
of this Warrant, on exercise of this Warrant at any time after the
consummation, effective date or record date of such event, shall receive, in
addition to the shares of Warrant Stock (or such other stock or securities)
issuable on such exercise prior to such date, the securities of the Company
to which such Registered Holder would have been entitled upon such date if
such Registered Holder had exercised this Warrant immediately prior thereto
(all subject to further adjustment as provided in this Warrant).

                   4.3      ADJUSTMENT FOR CAPITAL REORGANIZATION,
CONSOLIDATION, MERGER.

                             (a) Subject to Section 5.4, if any capital
reorganization of the capital stock of the Company, or any consolidation or
merger of the Company with or into another corporation, or the sale of all or
substantially all of the Company's assets to another corporation shall be
effected in such a way that holders of Warrant Stock will be entitled to
receive stock, securities or assets with respect to or in exchange for their
Warrant Stock, and in each such case, the Registered Holder of this Warrant,
upon the exercise of this Warrant (as provided in Section 1), at any time
after the consummation of such capital reorganization, consolidation, merger,
or sale, shall be entitled to receive, in lieu of the stock or other
securities and property receivable upon the exercise of this Warrant prior to
such consummation, the stock or other securities or property to which such
Registered Holder would have been entitled upon such consummation if such
Registered Holder had exercised this Warrant immediately prior thereto, all
subject to further adjustment as provided in this Section 6; and in each such
case, the terms of this Warrant shall be applicable to the shares of stock or
other securities or property receivable upon the exercise of this Warrant
after such consummation.

                             (b) In lieu of receiving the stock, securities
or assets as referred to in Section 4.3(a), the Holder of this Warrant shall
be entitled, at its option, to receive a warrant substantially similar to
this Warrant to be issued by the person acquiring the stock or assets of the
Company.

                  4.4        CONVERSION OF WARRANT STOCK. If all the
outstanding shares of the Series E Convertible Preferred Stock of the Company
are converted into Common Stock pursuant to the Company's Articles of
Incorporation or otherwise, or such Series E Convertible Preferred Stock

                                       4
<PAGE>

otherwise ceases to exist, then, from and after the date on which such Series
E Convertible Preferred Stock is so converted or ceases to exist (the
"CONVERSION DATE"): (i) this Warrant will be exercisable for Common Stock of
the Company and the term "Warrant Stock" (wherever used in this Warrant) will
thereafter mean the Company's Common Stock; and (ii) the Purchase Price will
be the price obtained by dividing (a) the Purchase Price in effect
immediately prior to the Conversion Date by (b) the number of shares of
Common Stock (including fractional shares) into which each share of Series E
Convertible Preferred Stock was convertible immediately prior to the
Conversion Date (subject to subsequent adjustment as provided herein).

         5.        NO IMPAIRMENT. Subject to the provisions of Section 4, the
Company will not, by amendment of its Articles of Incorporation or bylaws, or
through reorganization, consolidation, merger, dissolution, issue or sale of
securities, sale of assets or any other voluntary action, willfully avoid or
seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of
all such terms and in the taking of all such action as may be necessary or
appropriate in order to protect the rights of the Registered Holder of this
Warrant against impairment. Without limiting the generality of the foregoing,
subject to the provisions of Section 4, the Company (a) will not increase the
par value of any shares of stock issuable upon the exercise of this Warrant
above the amount payable therefor upon such exercise, and (b) will take all
such action as may be necessary or appropriate in order that the Company may
validly and legally issue fully paid and non-assessable shares of Warrant
Stock upon the exercise of this Warrant.

         6.        CERTIFICATE AS TO ADJUSTMENTS. In each case of any
adjustment in either the Purchase Price or in the number of shares of Warrant
Stock, or other stock, securities or property receivable on the exercise of
this Warrant, the Chief Financial Officer of the Company shall compute such
adjustment in accordance with the terms of this Warrant and prepare a
certificate setting forth such adjustment and showing in detail the facts
upon which such adjustment is based, including a statement of the adjusted
Purchase Price. The Company will forthwith mail a copy of each such
certificate to the Registered Holder of this Warrant.

         7.        NOTICES OF RECORD DATE. In case:

                   (a) the Company shall take a record of the holders of its
Warrant Stock (or other stock or securities at the time receivable upon the
exercise of this Warrant) for the purpose of entitling them to receive any
stock dividend; or

                   (b) of any consolidation or merger of the Company with or
into another corporation, or any conveyance of all or substantially all of
the assets of the Company to another corporation in which holders of the
Company's stock are to receive stock, securities or property of another
corporation; or

                   (c) of any voluntary dissolution, liquidation or
winding-up of the Company; or

                   (d) of any redemption or conversion into Common Stock of
all outstanding Warrant Stock;

                                       5
<PAGE>

then, and in each such case, the Company will mail or cause to be mailed to
the Registered Holder of this Warrant a notice specifying, as the case may
be, (i) the date on which a record is to be taken for the purpose of such
dividend, and stating the amount and character of such dividend, or (ii) the
date on which such consolidation, merger, conveyance, dissolution,
liquidation, winding-up, redemption or conversion is to take place, and the
time, if any is to be fixed, as of which the holders of record of Warrant
Stock or Common Stock (or such stock or securities as at the time are
receivable upon the exercise of this Warrant) shall be entitled to exchange
their shares of Warrant Stock or Common Stock (or such other stock or
securities) for securities or other property deliverable upon such
consolidation, merger, conveyance, dissolution, liquidation or winding-up.
Such notice shall be mailed at least ten (10) days prior to the date therein
specified.

         8.        LOSS OR MUTILATION. Upon receipt by the Company of
evidence reasonably satisfactory to it of the ownership of and the loss,
theft, destruction or mutilation of this Warrant, and of a written indemnity
agreement reasonably satisfactory to the Company, and (in the case of
mutilation) upon surrender and cancellation of this Warrant, the Company will
execute and deliver in lieu thereof a new Warrant of like tenor.

         9.        RESERVATION OF WARRANT STOCK. Subject to the provisions of
Section 5.4, the Company shall at all times reserve and keep available for
issue upon the exercise of this Warrant such number of its authorized but
unissued shares of Warrant Stock (and Common Stock if the Warrant Stock is
not Common Stock) as will be sufficient to permit the exercise in full of
this Warrant and the conversion of all shares of Warrant Stock issuable
hereunder into Common Stock (if the Warrant Stock is then convertible into
Common Stock).

         10.       NO RIGHTS OR LIABILITIES AS SHAREHOLDER. This Warrant does
not by itself entitle the Registered Holder to any voting rights or other
rights as a shareholder of the Company. In the absence of affirmative action
by Registered Holder to purchase Warrant Stock by exercise of this Warrant,
no pro- visions of this Warrant, and no enumeration herein of the rights or
privileges of the Registered Holder shall cause such Registered Holder to be
a shareholder of the Company for any purpose.

         11.       REPRESENTATIONS OF THE REGISTERED HOLDER. Because of the
exemptions from the registration and qualification requirements of the 1933
Act, and the California Corporation Securities Law of 1968, as amended or
such other applicable states' securities laws (the "LAW") relied upon by the
Company in issuing this Warrant and Warrant Stock to the Registered Holder,
the Registered Holder hereby represents and warrants to the Company that it:

                   11.1      By reason of its business or financial
experience, is able to evaluate the merits and risks of the investment in the
Warrant and Warrant Stock, and that it has the capacity to protect its own
interests with respect to this investment;

                   11.2      Is aware that the Warrant and Warrant Stock are
highly speculative and that there can be no assurance that it will receive
any return on this investment, and further, that

                                       6
<PAGE>

it has the financial ability to bear the economic risk of the investment and
has no need for liquidity with respect to the investment in the Warrant and
Warrant Stock;

                  11.3       Is aware of the Company's business affairs and
financial condition and: (a) has acquired sufficient information about the
Company to reach an informed and knowledgeable decision to acquire the
Warrant and Warrant Stock; (b) has been given the opportunity to ask
questions of and receive answers from the Company with respect to its
business and financial condition and with respect to the terms and conditions
of this investment; (c) has had the opportunity to obtain any additional
information necessary to verify any information received from the Company;

                  11.4       Is purchasing the Warrant and Warrant Stock for
investment for its own account only, not as nominee or agent, and not with a
view to, or for resale in connection with, any "distribution" of all or any
part of such securities within the meaning of the 1933 Act;

                  11.5       Understands that the Warrant and Warrant Stock
have not been registered under the 1933 Act by reason of a specific exemption
therefrom, which exemption may depend upon, among other things, the truth of
its representations as expressed in this Warrant;

                  11.6       Understands that: (a) the Warrant and Warrant
Stock are characterized as "restricted securities" under the federal
securities laws since the sale of the Warrant and Warrant Stock has not been
registered under the 1933 Act; (b) the Warrant and Warrant Stock may be
resold without registration under the 1933 Act only in certain limited
circumstances; (c) the Registered Holder may be required to hold the Warrant
and Warrant Stock indefinitely unless such securities are subsequently
registered under the 1933 Act or an exemption from such registration is
available; and (d) the Company is not obligated to register such securities
under the 1933 Act or assist the Registered Holder in qualifying for any
exemption from registration under the 1933 Act;

                  11.7       Is aware of Rule 144 promulgated under the 1933
Act, which rule provides, in substance, that (a) after one (1) year from the
date the securities have been purchased and fully paid for, a purchaser may
publicly transfer restricted securities provided certain conditions are met,
e.g., certain public information is available about the Company, and specific
limitations on the amount of shares which can be sold within certain periods
and the manner in which such shares must be sold are complied with, and (b)
after two (2) years from the date the securities have been purchased and
fully paid for, purchasers who are not "affiliates" of the Company may sell
restricted securities without satisfying such conditions;

                  11.8       Further understands that if the requirements of
Rule 144 are not met, registration under the 1933 Act, compliance with
Regulation A, or some other registration exemption will be required for any
disposition of the Warrant or Warrant Stock; and that, although Rule 144 is
not exclusive, the SEC has expressed its opinion that persons proposing to
sell restricted securities other than in a registered offering and other than
pursuant to Rule 144 will have a substantial burden of proof in establishing
that an exemption from registration is

                                       7
<PAGE>

available for such offers or sales and that such persons and the brokers who
participate in the transactions do so at their own risk;

                  11.9       Agrees that the Company may place the legends
set forth below or similar legends on any stock certificate(s) evidencing the
Warrant Shares, together with any other legends that may be required by state
or federal securities laws, the Company's Articles of Incorporation or
Bylaws, any other agreement between Registered Holder and the Company or any
agreement between the Registered Holder and any third party:

         THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
         SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER THE
         SECURITIES LAWS OF ANY OTHER JURISDICTIONS. THESE SECURITIES ARE
         SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE
         TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND
         APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR
         EXEMPTION THEREFROM. INVESTORS SHOULD BE AWARE THAT THEY MAY BE
         REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN
         INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY
         REQUIRE AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO
         THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN
         COMPLIANCE WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

         THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A 180 DAY
         MARKET STAND-OFF RESTRICTION AS SET FORTH IN A CERTAIN WARRANT
         AGREEMENT BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE
         SHARES, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF
         THE ISSUER. AS A RESULT OF SUCH AGREEMENT, THESE SHARES MAY NOT BE
         TRADED PRIOR TO 180 DAYS AFTER THE EFFECTIVE DATE OF THE INITIAL
         PUBLIC OFFERING OF THE COMMON STOCK OF THE ISSUER HEREOF. SUCH
         RESTRICTIONS SHALL BE BINDING ON TRANSFEREES OF THESE SHARES.

         Registered Holder agrees that, in order to ensure compliance with
the restrictions imposed by this Warrant, the Company may issue appropriate
"stop-transfer" instructions to its transfer agent, if any, and if the
Company transfers its own securities, it may make appropriate notations to
the same effect in its own records.

         12.       "MARKET STAND-OFF" AGREEMENT. Registered Holder agrees in
connection with any registration of the Company's securities under the 1933
Act that, upon the request of the Company or the underwriters managing any
registered public offering of the Company's securities, Registered Holder
will not sell or otherwise dispose of any shares of the Warrant Stock without
the prior written consent of the Company or such underwriters, as the case
may be, for such period of time (not to exceed one hundred eighty (180) days)
after the effective date of

                                       8
<PAGE>

such registration requested by such managing underwriters and subject to all
restrictions as the Company or the managing underwriters may specify for
employee-shareholders generally. Registered Holder further agrees to enter
into any agreement reasonably required by the underwriters to implement the
foregoing.

         13.       FINANCIAL INFORMATION. The Company shall provide the
Registered Holder with quarterly financial statements so long as the Company
is profitable.

         14.       NOTICES. All notices and other communications from the
Company to the Registered Holder shall be mailed by first-class registered or
certified mail, postage prepaid, to the address furnished to the Company in
writing by the last Registered Holder who shall have furnished an address to
the Company in writing.

         15.       CHANGE; WAIVER. Neither this Warrant nor any term hereof
may be changed, waived, discharged or terminated orally but only by an
instrument in writing signed by the party against which enforcement of the
change, waiver, discharge or termination is sought.

         16.       HEADINGS. The headings in this Warrant are for purposes of
convenience in reference only, and shall not be deemed to constitute a part
hereof.

         17.       LAW GOVERNING. This Warrant shall be construed and
enforced in accordance with, and governed by, the internal laws of the State
of California, excluding that body of law applicable to conflicts of law.

         18.       TERMS BINDING. By acceptance of this Warrant, the
Registered Holder of this Warrant (and each subsequent assignee, transferee
or Registered Holder of this Warrant) accepts and agrees to be bound by all
the terms and conditions of this Warrant.

Dated: March 8, 2000

                         ACKNOWLEDGED AND ACCEPTED BY:

CIPHERGEN BIOSYSTEMS, INC.                  REGISTERED HOLDER:

By:                                         By:
   ------------------------------              -------------------------------

Name:                                       Name:
     ----------------------------                -----------------------------

Title:                                      Title:
     ----------------------------                -----------------------------

                                       9

<PAGE>

                                                                     EXHIBIT 1

                              FORM OF SUBSCRIPTION

                   (To be signed only upon exercise of Warrant)

To:      Ciphergen Biosystems, Inc.
         490 San Antonio Road
         Palo Alto, CA 94306

         (1) The undersigned Holder hereby elects to purchase ________________
shares of Series E Convertible Preferred Stock of _______________ (the "WARRANT
STOCK"), pursuant to the terms of the attached Warrant, and tenders herewith
payment of the purchase price for such shares in full.

         [(1) NET EXERCISE ELECTION. THE UNDERSIGNED HOLDER ELECTS TO CONVERT
THE WARRANT INTO SHARES OF WARRANT STOCK BY NET EXERCISE ELECTION PURSUANT TO
SECTION 1.6 OF THE WARRANT. THIS CONVERSION IS EXERCISED WITH RESPECT TO
__________ SHARES OF SERIES E CONVERTIBLE PREFERRED STOCK OF _______________
(THE "WARRANT STOCK") COVERED BY THE WARRANT.]

                  [STRIKE PARAGRAPH ABOVE THAT DOES NOT APPLY]

         (2) In exercising the Warrant, the undersigned Holder hereby
confirms and acknowledges that the representations and warranties set forth
in Section 12 of the Warrant as they apply to the undersigned Holder continue
to be true and correct as of this date.

         (3) Please issue a certificate or certificates representing such
shares of Warrant Stock in the name or names specified below:

--------------------------------            ----------------------------------
(Name)                                      (Name)

--------------------------------            ----------------------------------
(Address)                                   (Address)

--------------------------------            ----------------------------------
(City, State, Zip Code)                     (City, State, Zip Code)

--------------------------------            ----------------------------------
(Federal Tax Identification Number)         (Federal Tax Identification Number)

--------------------------------            ----------------------------------
(Date)                                      (Signature of Holder)

                                       10

<PAGE>

                               FORM OF ASSIGNMENT

         FOR VALUE RECEIVED the undersigned Registered Holder of this Warrant
hereby sells, assigns and transfers unto the Assignee named below all of the
rights of the undersigned under the within Warrant, with respect to the
number of shares of Series E Convertible Preferred Stock set forth below:

   NAME OF ASSIGNEE               ADDRESS                  NO. OF SHARES
----------------------         -------------            -------------------

and does hereby irrevocably constitute and appoint ________________ Attorney
to make such transfer on the books of ___________________, maintained for the
purpose, with full power of substitution in the premises.

Dated:  _____________________               [Registered Holder]

                                            By:
                                               -------------------------------
                                            Name:
                                                 -----------------------------
                                            Title:
                                                  ----------------------------

                                       11<PAGE>

                             JOINT VENTURE AGREEMENT

         This Joint Venture Agreement ("Agreement") is entered into as of the
Effective Date (as defined below) by Ciphergen Biosystems, Inc., a California
corporation located at 490 San Antonio Road, Palo Alto, California 94306,
U.S.A. ("CBI") and Sumitomo Corporation, a Japanese corporation located at
1-2-2 Hitotsubashi Chiyoda-ku, Tokyo 100-8601, Japan ("SC"). Upon Closing (as
defined below), JVC (as defined below) shall sign and become a Party (as
defined below) to this Agreement. The Parties (as defined below) agree as
follows:

1.       DEFINITIONS

         For the purpose of this Agreement, the following definitions shall
apply:

         1.1 "AFFILIATE" means any entity which is controlled by CBI, SC or
JVC. An entity shall be regarded as in control of another entity for purposes
of this definition if it owns or controls more than fifty percent (50%) of
the shares of the subject entity entitled to vote in the election of
directors (or, in the case of an entity that is not a corporation, for the
election of the corresponding managing authority); provided, however, that in
any country where the local law does not permit equity participation of at
least 50%, then Affiliate will include any company in which CBI, SC or JVC
owns or controls, directly or indirectly, the maximum percentage of such
outstanding stock or voting rights permitted by law.

         1.2 "ANNUAL BUDGET" means an estimate of JVC's revenues and
expenditures for a specified fiscal year prepared annually by the JVC and
presented to JVC's Board on the first quarterly meeting of each fiscal year,
submitted as a part of the Business Plan in Section 1.6.

         1.3 "ARTICLES" means the Japanese language version of the Articles
of Incorporation of JVC attached in the English language as EXHIBIT A, and
includes any amendments made under this Agreement and the Commercial Code of
Japan.

         1.4 "BOARD" means the board of directors of JVC.

         1.5 "BOOK VALUE" means JVC's tangible net worth (tangible assets
minus total liabilities) at the end of the specified accounting period as
defined in Japan GAAP and disclosed in JVC's Financial Statements audited by
JVC's public accountants.

         1.6 "BUSINESS PLAN" means a plan of JVC operations, management,
financial and other business matters presented and approved by the Board on
the first quarterly meeting of each fiscal year.

         1.7 "BUYOUT OPTION" means CBI's option to purchase JVC shares from
SC as provided in Section 5.

         1.8 "CBI IPO" means initial underwritten public offering of CBI's
equity securities on a national securities exchange or the Nasdaq National or
Small Cap Markets.

<PAGE>

         1.9 "CHANGE IN CONTROL" with respect to a Party means (i) a merger
of that Party with or into another Person, or a sale of all or substantially
all of a Party's assets to another Person, if as a result of the merger or
asset sale the holders of a majority of the Party's voting securities before
the transaction hold less than a majority of the voting securities of the
surviving entity, or (ii) the acquisition by a Person or a group acting in
concert of a majority of a Party's voting securities.

         1.10 "CLOSING" is defined in Section 9.3.

         1.11 "DISTRIBUTION AND MARKETING AGREEMENT" means the Distribution
and Marketing Agreement to be entered into by CBI and JVC attached in EXHIBIT
B.

         1.12 "EFFECTIVE DATE" means the date on which CBI and SC have
executed this Agreement.

         1.13 "FAIR MARKET VALUE" is defined in Section 10.8.

         1.14 "FINANCIAL STATEMENTS" is defined in Section 4.5(a).

         1.15 "HOLDER" means CBI or SC, as applicable. "HOLDERS" means CBI
and SC.

         1.16 "JAPAN GAAP" means generally accepted accounting principles as
applied in Japan.

         1.17 "JVC IPO" means initial underwritten public offering of JVC's
Shares on a national securities exchange in the United States or Japan, the
over-the-counter securities market in Japan, or the Nasdaq National or Small
Cap Markets in the United States.

         1.18 "JVC" means the limited liability corporation (KABUSHIKI
KAISHA) to be incorporated under the Commercial Code of Japan with the
English language name "Ciphergen Biosystems K.K."

         1.19 "JVC INTEREST" means Shares held by the Holders.

         1.20 "OPTION SHARES" is defined in Section 5.1.

         1.21 "PARTY" or "PARTIES" means CBI, SC or JVC, as applicable.

         1.22 "PERSON" means a natural individual, partnership, firm,
company, corporation, and any other form of business association.

         1.23 "PRO RATA SHARE" of a Holder means the percentage of JVC
Interest that the Holder holds by virtue of those Shares owned by that
Holder, after assuming conversion or exercise of any warrant, stock option
and other securities of JVC.

         1.24 "REPRESENTATIVE DIRECTOR" is defined in Section 4.1(d).

                                       -2-
<PAGE>

         1.25 "REPRESENTATIVE DIRECTOR AGREEMENT" means the Representative
Director Agreement to be entered into by the JVC and the Representative
Director attached in EXHIBIT C.

         1.26 "SC INTEREST RATE" means rate of interest charged on Working
Capital Loans from SC to JVC as provided in Section 2.4.

         1.27 "SHARE" or "SHARES" means shares of JVC Common Stock with a par
value of Y50,000 per share, as specified in the Articles.

         1.28 "SHAREHOLDING RATIO" means the ratio of the number of a
Holder's Shares to all outstanding Shares, after assuming conversion or
exercise of any warrant, stock option and other equity securities of JVC.

         1.29 "U.S. GAAP" means the generally accepted accounting principles
as applied in the United States.

         1.30 "WORKING CAPITAL LOAN" is defined in Section 2.4(a).

         1.31 "TERMINATING EVENT" means any event which gives a Holder the
right to notify the other Holder of termination of this Agreement under
Section 10.

2.       JVC ORGANIZATION AND CAPITAL STRUCTURE

         2.1 INCORPORATION PROCEDURE AND DOCUMENTATION. SC shall be
responsible for the incorporation of JVC and file the application for
registration of incorporation as soon as practicable. SC, as the promoter,
shall prepare all documents necessary to establish JVC as provided in this
Agreement and to allow the Holders to subscribe for JVC's Shares pursuant to
Section 2.3. SC shall select a bank in Japan for the deposit of initial
paid-in capital ("Deposit Bank"). The initial paid-in capital shall be sent
to an account (BETSUDAN YOKIN) designated by the Deposit Bank, and the
Deposit Bank shall issue a certificate of custody required for the
registration of incorporation. Except as approved by CBI, SC shall deliver to
CBI a complete and accurate English language translation of (i) the Articles,
(ii) the commercial registration of JVC as of a recent date, and (iii) all
such incorporation, subscription and other documents required to be prepared
in the Japanese language. All such documents not required to be prepared in
the Japanese language shall be prepared and executed in the English language.
Pursuant to Section 9.4(b), SC shall provide CBI with a reasonably itemized
listing of the out-of-pocket costs SC incurred in incorporating JVC and
causing its initial share issuances, which shall be reimbursed by the JVC
within 30 days after the Closing.

         2.2 CAPITALIZATION. JVC shall have 10,000 authorized Shares.

         2.3 SUBSCRIPTION. At the incorporation of JVC, (i) 1,750 Shares
shall be issued to SC at the issue price of Y50,000 per Share for an
aggregate issue price of Y87,500,000, and at Closing, (ii) 750 Shares shall
be issued to CBI at the issue price of Y50,000 per Share for an aggregate
issue price of Y37,500,000. Documents for subscription of Shares shall be
prepared in the names of the Holders, and JVC shall issue to SC and CBI
certificates evidencing the Shares purchased.

                                       -3-
<PAGE>

         2.4 SC WORKING CAPITAL LOANS TO JVC.

                  (a) LOAN TO JVC. SC shall arrange to lend JVC, from the
Effective Date to the date that CBI exercises the Buyout Option ("Working
Capital Loan Period"), all amounts reasonably required by JVC to fund JVC's
operations in the manner described in the Business Plan, to the extent funds
received in the initial stock issuance, plus cash generated by JVC operations
are not sufficient ("Working Capital Loan"). JVC may draw the Working Capital
Loan from an immediately available line of credit from an account designated
by SC to JVC. SC shall advance the Working Capital Loan to JVC at any time
during the Working Capital Loan Period ("Working Capital Advance") provided
that JVC gives SC a 48 hour notice ("Working Capital Loan Notice") before the
Working Capital Advance is to be made. JVC or CBI shall not have any
additional obligation to SC or any other Person as a result of the Working
Capital Loan.

                  (b) WORKING CAPITAL LOAN INTEREST. JVC shall pay interest
on the unpaid aggregate principal amount of the outstanding Working Capital
Loan advanced to JVC from the date of the Working Capital Advance until the
next date on which SC makes another Working Capital Advance, at the rate
applicable on the date of Working Capital Advance as SC notifies JVC in
writing at that time ("SC Interest Rate") until the next date of Working
Capital Advance. SC shall provide the JVC with a schedule of applicable
interest rates and use its best efforts to provide the lowest interest rate.
Payments on accrued Working Capital interest shall be made 10 days after the
last day of each month during the Working Capital Loan Period. When SC makes
available a subsequent Working Capital Advance, the interest rate for the
aggregate principal amount plus accrued interest shall be the SC Interest
Rate applicable on the date of that subsequent Working Capital Advance. The
Working Capital interest shall be computed, for actual days elapsed, as if
each full calendar year consisted of 360 days. The Working Capital Loan
interest shall be limited by the Interest Rate Restriction Law (RISOKU
SEIGENHO).

                  (c) WORKING CAPITAL LOAN TERMINATION. JVC shall pay SC any
outstanding balance of the Working Capital Loan, plus continuing Working
Capital Loan Interest (i) within 10 days after CBI's exercise of the Buyout
Option, (ii) immediately upon JVC's bankruptcy, JVC ceasing to do business,
JVC's dissolution or liquidation, or (iii) upon the termination of this
Agreement following a Termination Event under Section 10.

                  (d) PREPAYMENTS. JVC shall have the right to prepay the
Working Capital Loan ("Prepayments") amount at any time during the Working
Capital Loan Period, in whole or in part, without premium or penalty. JVC
shall give SC notice of each such Prepayment. All Prepayments shall be
applied first to accrued and unpaid interest and then to the principal
balance of the Working Capital Loan. Such Prepayments shall not affect the
availability of the Working Capital Loan for the benefit of JVC.

                  (e) DISBURSEMENT. Each Working Capital Advance shall be
disbursed to JVC after the Working Capital Loan Notice and added to the
principal amount of the Working Capital Loan and interest shall accrue at the
SC Interest Rate applicable on the disbursement date until the next
disbursement date.

                                       -4-
<PAGE>

                  (f) RECORDS. All Working Capital Loan Advances, interest on
the Working Capital Loan, Prepayments of the principal amount of the Working
Capital Loan, Working Capital Loan Payment, wire transfers and other related
transactions shall be recorded and kept up to date by the JVC. JVC's failure
to maintain such records shall not affect JVC's obligations to repay the
Working Capital Loan.

                  (g) SECURITY INTEREST. The Working Capital Loan shall not
be supported by any security interest or guaranty.

                  (h) DEFAULT AND ACCELERATION. If after CBI exercises the
Buyout Option, (i) JVC fails to pay the principal of or interest on the
Working Capital Loan when due, (ii) JVC files for bankruptcy proceedings,
(iii) JVC's creditors file for JVC's bankruptcy and the case has not been
dismissed in 60 days, or (iv) JVC ceases to do business or liquidates, then
the Working Capital Loan shall terminate and the entire unpaid balance of the
principal of and interest on the Working Capital Loan shall immediately
become due and payable upon written notice to JVC.

                  (j) FINANCING AFTER CBI EXERCISE OF BUYOUT OPTION. After
CBI exercises the Buyout Option and until the JVC IPO, CBI shall use its best
efforts to obtain financing for the JVC. If CBI is not able to obtain such
financing, then until the JVC IPO, CBI shall provide JVC with Working Capital
Loans on the best terms then available. JVC shall pay the outstanding balance
of the post-CBI Buyout Working Capital Loan, plus the total Working Capital
Loan Interest, upon (i) JVC IPO, or (ii) on demand by CBI to the extent that
after payment of the post CBI-Buyout Working Capital Loan and Working Capital
Loan Interest, JVC has sufficient working capital.

3.       JVC BUSINESS

         3.1 PURPOSE. The main purpose of the JVC shall be to distribute and
market CBI's Systems and Consumables (as defined in Section 1 of the
Distribution and Marketing Agreement as attached) in the life sciences
research market in Japan as provided in the Distribution and Marketing
Agreement.

         3.2 SC MARKETING SUPPORT. Until CBI exercises its Buyout Option, SC
shall provide marketing support to JVC. In consideration for SC's marketing
support, until CBI exercises its Buyout Option, JVC shall pay SC 20% of U.S.
list price for CBI's Systems and Consumables purchased by JVC from CBI and
sold to JVC customers in Japan within 10 days of the month end following
payments from JVC customers to JVC.

         3.3 JVC INITIAL PUBLIC OFFERING IN JAPAN. Each Holder shall cause
JVC to take all actions reasonably necessary to permit JVC to effect a JVC
IPO, such as (i) conducting its business in accordance with applicable law
and regulations, (ii) maintaining adequate records, (iii) obtaining an annual
audit of JVC's Financial Statements in Section 4.5(b), (iv) other reasonably
necessary actions. Each Holder shall cause JVC to not take any action
reasonably expected to prevent or delay a JVC IPO, such as (i) not issuing
any additional Shares and satisfying its financing needs through borrowing,
and (ii) not entering into any merger transaction or sell or purchase any
significant business so long as and to the extent that the rules of any
Japanese national securities exchange or the Japanese OTC market prohibit
stock issuances, merger transactions or the sale or purchase of any

                                       -5-
<PAGE>

significant business during the period starting on the date one year prior to
the end of the most recently concluded fiscal year of JVC and ending on the
date of listing or OTC registration, (iii) other actions reasonably expected
to prevent or delay a JVC IPO. However, this Section 3.3 does not require a
Holder to take any action which it reasonably believes would be detrimental
to JVC's or the Holder's business and does not constitute any representation
or warranty by a Holder that a JVC IPO shall occur.

4.       MANAGEMENT OF JVC

         4.1 BOARD OF DIRECTORS.

                  (a) DIRECTOR POSITIONS BEFORE EXERCISE OF BUYOUT OPTION.
The Board shall have three authorized positions. Until CBI exercises the
Buyout Option, SC as Holder of majority Shares shall have the right to
nominate two Board members (one of whom shall be JVC's President and Chief
Executive Officer), and CBI as Holder of minority Shares shall have the right
to nominate one Board member. Each Holder shall nominate to the Board only
individuals who are active in JVC's field of business or related fields of
business. Any vacancy on the Board shall be filled pursuant to the nomination
procedure described in this Section 4.1(a). The (or one of the) CBI
director(s) shall be Chairman of the Board.

                  (b) DIRECTOR POSITIONS AFTER EXERCISE OF BUYOUT OPTION. If
CBI exercises the Buyout Option, SC shall immediately cause one of the SC
nominees to resign from JVC's Board. After the Buyout Option, CBI as Holder
of majority Shares shall have the ongoing right to nominate two Board members
and SC as Holder of minority Shares shall have the ongoing right to nominate
one Board member.

                  (c) REMOVAL. A Holder shall have the right to request
removal of any director which such Holder is entitled to nominate at any time
effective upon notice to JVC, the director to be removed and to the other
Holder. SC and CBI shall vote all voting Shares held by them or as to which
they have the right to direct the vote so as to elect the other Holder's
nominees, remove directors for whom removal has been requested, and maintain
the Board constituency described in this Section 4.1.

                  (d) REPRESENTATIVE DIRECTOR. The President and Chief
Executive Officer of JVC and the (or one of the) director or directors
designated by a Holder of minority Shares shall each be a Representative
Director of JVC and each enter into the Representative Director Agreement in
a form substantially similar to EXHIBIT C. If the individual designated by
the Holder of minority Shares resigns as Representative Director or becomes
unable to serve, another individual shall be designated to be a
Representative Director.

                  (e) COMPENSATION AND EXPENSES. Directors of JVC shall serve
without compensation unless the position of JVC director is his or her
full-time occupation. No JVC director shall receive a retirement payment for
his or her service in that position. Each Holder shall indemnify the other
Holder and JVC against any other claim for compensation for service as a
director of JVC made by a director nominated by that Holder. JVC shall
reimburse reasonable travel costs of any director attending a Board meeting.

                                       -6-
<PAGE>

                  (f) BOARD MEETINGS. Directors of JVC shall meet in Tokyo,
Japan and Palo Alto, California, alternatively, for quarterly Board meetings.

                  (g) BOARD QUORUM AND APPROVAL Without limiting the
Articles, a quorum of the Board shall be deemed present at any duly noticed
regular or special meeting if a majority of the directors including at least
one director nominated by CBI and one director nominated by SC are present
physically, and (to the extent permitted by the Japanese Commercial Code)
present by telephone, video conference or otherwise. Without limiting the
Articles, any action or determination by the Board shall require the
affirmative vote of a majority of the Board members present at the meeting.

         4.2 OFFICERS.

                  (a) PRESIDENT AND CHIEF EXECUTIVE OFFICER OF JVC. The
President shall be the Chief Executive Officer ("CEO") of JVC. Mr. Toru
Umehara shall be JVC's Interim President and Interim Chief Executive Officer
and shall work at least 50% for the JVC. SC shall assist CBI in searching for
and recruiting a senior Japanese biotechnology industry executive to serve
permanently as JVC's President and CEO. The Board shall elect as President
and CEO the individual selected by SC and approved by CBI, which approval
shall not be unreasonably withheld. Upon such election SC shall cause the
Interim President and Interim CEO to resign as President and CEO and as a
director unless SC wishes to nominate him as an SC director.

                  (b) VICE PRESIDENT. JVC's Vice President of Marketing and
Sales shall be Mr. Tsuyoshi Karasawa. He shall work 100% for the JVC until a
new President and CEO is elected by the Board. He shall work 75% for the JVC
after the new President and CEO is appointed.

                  (c) OTHER OFFICERS Other officers of JVC and JVC's
management reporting structure shall be determined by the Board.

         4.3 EMPLOYEE MATTERS.

                  (a) LOANED EMPLOYEES. If the Board and a Holder agree that
a Holder or its Affiliate will loan an employee on a full- or part-time basis
to JVC, then JVC shall reimburse the lender for the salary and benefits
actually paid to such employee during the period loaned to JVC, pro-rated
based on the percentage of time the employee works for JVC. JVC shall not
bear any other costs of loaned employees.

                  (b) CONFIDENTIALITY. Each JVC employee, and any employee of
another entity working for JVC but not a regular employee of JVC, shall each
sign CBI's standard form confidentiality agreement providing for
confidentiality of information or data disclosed by JVC or CBI and for
ownership by CBI of inventions or original works of authorship created by
such individuals.

         4.4 STATUTORY AUDITOR. Except as required by applicable law, JVC
shall have one statutory auditor. CBI shall nominate the statutory auditor,
subject to SC's approval, which shall not be unreasonably withheld.

                                       -7-
<PAGE>

         4.5 FINANCIAL STATEMENTS AND ACCOUNTING RECORDS. JVC's financial
year shall be January 1 through December 31 of every year. JVC's auditors
shall be Price Waterhouse Coopers in Japan. JVC shall maintain its accounting
records and prepare its Financial Statements (as defined below) in compliance
with Japan GAAP. All Financial Statements provided to CBI shall be in English.

                  (a) UNAUDITED MONTHLY FINANCIAL STATEMENTS. JVC shall
provide each Holder with a monthly unaudited balance sheet, profit and loss
statement and statement of sources and uses of cash ("Financial Statements")
within 30 days after each month-end.

                  (b) AUDITED ANNUAL FINANCIAL STATEMENTS. JVC shall provide
each Holder with audited Financial Statements within 120 days after each
fiscal year end.

                  (c) CBI'S ADDITIONAL INFORMATION RIGHTS. Until the CBI IPO,
JVC shall provide CBI with a reconciliation of JVC's annual audited Financial
Statements according to U.S. GAAP when JVC delivers its audited Financial
Statements. After the CBI IPO, JVC shall continue to provide CBI with monthly
unaudited Financial Statements and provide (i) quarterly unaudited Financial
Statements within 30 days after the end of each fiscal quarter, and (ii)
annual audited Financial Statements within 75 days after the end of each
fiscal year, in each case prepared according to U.S. GAAP.

         4.6 JVC BUSINESS PLAN. An English version of the annual Business
Plan shall be produced. The Business Plan shall include, without limitation,
(i) promotion strategy and tactics, (ii) sales and marketing plans, (iii) the
Annual Budget, and (iv) other items relating to distribution and marketing of
CBI Systems and Consumables. CBI shall review and approve the Business Plan
on the first quarterly meeting of each fiscal year. The Board shall discuss,
update and approve the Business Plan at least once every fiscal year.

         4.7 RIGHT OF INSPECTION. During office hours of JVC, the Holders
shall have full access to all properties, books of account, records and the
like of JVC with the right to make copies. Any information obtained by the
Holders through exercise of this right shall (i) be used by such Holder only
for purposes which are consistent with its status as an equity Holder in JVC
and not for the pursuit of business interests outside JVC (except to the
extent such Holder shall otherwise have rights for access to such information
or to the extent used to determine compliance with this Agreement) and (ii)
be subject to the confidentiality provisions of Section 11.1.

         4.8 MATTERS REQUIRING APPROVAL OF HOLDERS. The following actions
shall not be taken by JVC without prior approval of both Holders. A Holder's
approval shall be considered given if one of the directors nominated by that
Holder votes at a Board meeting or takes action by written consent in favor
of such action.

                  (a) Making any basic change in the general nature or scope
of business of JVC, including entering a new line of business.

                                      -8-
<PAGE>

                  (b) Amending the Articles of JVC, including, without
limitation, increasing or decreasing the number of authorized Shares of JVC,
changing the rights, preferences or privileges of the Shares and increasing
or decreasing the authorized number of directors on the Board.

                  (c) Removing the director nominated by the other Holder,
unless the director has violated his fiduciary obligations to JVC or has
caused JVC to act in a manner intended to harm the other Holder.

                  (d) Dissolving or liquidating JVC before and until CBI
exercises the Buyout Option.

                  (e) Issuing any Shares, securities convertible into Shares
or debt securities (but excluding Working Capital Loans).

                  (f) Redeeming or canceling Shares.

                  (g) Merging or consolidating JVC with another Person, or
selling, leasing, pledging, mortgaging, encumbering or otherwise disposing
all or substantially all of the assets of JVC, whether in one transaction or
a series of transactions.

                  (h) Establishing a business relationship with any direct
competitor of CBI.

                  (i) Allowing a Holder to engage in JVC's field of business
that materially competes with JVC and therefore violates Section 7 of this
Agreement.

                  (j) Investing in any other Person.

                  (k) Entering into any agreement with any director or
shareholder of JVC or an Affiliate of such director or shareholder (except
this Agreement and the other agreements contemplated hereby).

                  (l) Changing JVC's executive management or management
structure.

                  (m) Declaring dividends.

                  (n) Acquiring assets for consideration in excess of
Y31,250,000.

                  (o) Borrowing in excess of Y12,500,000 (except for Working
Capital Loans).

                  (p) Approving annual budgets and any business plans.

                  (q) Selling or licensing technology developed by the JVC to
third parties, or encumbering such technology.

                  (r) Licensing or sublicensing CBI's technology.

                  (s) Transferring or sublicensing distribution, sale and
marketing rights.

                                       -9-
<PAGE>

                  (t) Opening a branch office.

                  (u) Approving the sale or assignment of Shares.

                  (v) Terminating this Agreement without following the
Termination procedures as set forth in Section 10 of this Agreement.

                  (w) Entering into any material transactions except in the
ordinary course of business.

                  (x) Effecting a JVC IPO.

                  (y) Amending, attaching any addendum or addenda to any of
the terms of this Agreement.

5.       CBI BUYOUT OPTION.

         5.1 OPTION RIGHT AND EXERCISE PRICE. Until November 30 of each year
commencing with November 30, 2001, CBI shall have the right ("Buyout Option")
to purchase from SC 1,000 Shares (or such greater number of Shares as is
necessary for CBI to hold, after the purchase, 70% of the then outstanding
Shares) ("Option Shares"). The Buyout Option shall terminate automatically
after November 30, 2004. The aggregate purchase price for the Option Shares
shall be Y50,000,000, or if greater than Y50,000,000 the larger of:

                  (a) 8% of JVC's Net Sales during the calendar year ending
on the date CBI exercises the Buyout Option, or

                  (b) 40% of JVC's Book Value on December 31 of the year in
which CBI exercises the Buyout Option.

         5.2          BUYOUT OPTION PROCEDURES.

                  (a) Before November 15 of each year in which the Buyout
Option may be exercised, JVC shall provide CBI JVC's estimated year-end
Financial Statements prepared in accordance with Japan GAAP. CBI shall give
SC CBI's written notice ("Buyout Notice") as to whether CBI exercises the
Buyout Option on or before 9:00 a.m. on November 30, Tokyo time. SC shall
elect within 10 days after CBI's Buyout Notice whether to have CBI pay the
exercise price in cash or in CBI stock.

                  (b) CBI's exercise of the Buyout Option and its election as
to the form of payment shall be irrevocable, except that CBI shall have the
right to revoke its exercise, for 10 days after CBI receives JVC's audited
Financial Statements for the fiscal year at the end of which CBI exercised
the Buyout Option, if such audited Financial Statements show that JVC's Net
Sales or Book Value were more than 10% higher or lower than the estimated
year-end Financial Statements provided to CBI under Section 5.2(a).

                                       -10-
<PAGE>

         5.3 BUYOUT OPTION PAYMENTS. CBI's obligation to pay the Buyout
Option exercise price shall first arise when CBI receives JVC's audited
Financial Statements for the fiscal year at the end of which CBI elected to
exercise the Buyout Option. If SC has elected to be paid the exercise price
in cash, CBI shall pay SC the exercise price within 10 days after CBI
receives such audited Financial Statements. If SC elects to be paid the
exercise price with CBI stock, the number of shares of CBI Common Stock to be
issued shall be determined by dividing the exercise price (i) if the CBI IPO
has not yet occurred, the same price per share of the CBI Preferred Stock in
the most recent private financing or (ii) if the CBI IPO has occurred, the
average of the closing price of CBI Common Stock over the 30-day period
ending 3 business days before the exercise of the Buyout Option. Any shares
issued shall be pursuant to a "private placement" exemption from the
registration requirements of U.S. state and federal securities laws and
subject to transfer restrictions and legends on stock certificates to the
extent required by such laws and regulations. The transfer of the Option
Shares, and the transfer of the cash or stock to be paid by CBI, will occur
at CBI's office. At that closing, SC will deliver to CBI a certificate
representing the Option Shares in the name of CBI and registered by JVC, and
CBI shall deliver to SC payment by check or wire transfer of immediately
available funds if the exercise price is being paid in cash, or a certificate
representing the shares of CBI Common Stock to be delivered in the name of
SC. SC will deliver a written statement to CBI that the Option Shares are
free of all liens and other encumbrances, and if CBI is delivering CBI Common
Stock, CBI will deliver to SC a written statement that the shares of CBI
Common Stock are free of all liens and other encumbrances (other than
restrictions on transfer under applicable law).

6.       PERMITTED TRANSFERS; RIGHT OF FIRST REFUSAL

         6.1 RESTRICTIONS. CBI and SC agree to hold their respective JVC
Interest from the Effective Date to CBI's exercise of the Buyout Option,
subject to this Section 6. CBI and SC further agree not to transfer, sell,
assign, hypothecate or in any way alienate any of such Holder's Shares or any
right or interest therein except as provided below:

                  (a) Before the CBI Buyout Option is exercised pursuant to
Section 5, neither Holder shall be permitted to so transfer its Shares
without the prior written consent of the other Holder.

                  (b) After the CBI Buyout Option is exercised pursuant to
Section 5, either Holder may transfer such Holder's Shares; provided that the
non-offering Holder shall have the right to purchase all (but not less than
all) of the Shares offered by the offering Holder ("Right of First Refusal"),
which right shall be exercisable by written notice ("Right of First Refusal
Notice") to the offering Holder not later than the expiration of 30 days
after delivery of the offering Holder's written notice of intention to sell.
The price and terms for the non-offering Holder shall be the price and terms
stated in the offering Holder's Right of First Refusal Notice.

                  (c) If the non-offering Holder does not exercise its Right
of First Refusal on the offered Shares within such 30-day period in Section
6.1(b) above, the offering Holder may within 60 days after expiration of such
Right of First Refusal, sell or transfer its Shares to a transferee or
transferees named in the Right of First Refusal Notice; provided that (i)
such sale or

                                       -11-
<PAGE>

transfer is not at a lower price or on terms more favorable to the transferee
or transferees than those specified in the Right of First Refusal Notice;
(ii) prior to such sale or transfer, such transferee or transferees agree in
writing to become bound by all obligations of the transferor under this
Agreement; and (iii) any such sale or transfer shall not serve to excuse or
terminate any of the obligations of the transferor either hereunder or under
a related agreement to which the transferor is a party if such related
agreement does not provide for such excuse or termination upon such transfer.

                  (d) The restrictions and other provisions of this Section 6
shall apply to any Shares acquired by a Holder.

                  (e) The instruments representing the Shares shall bear a
legend stating that such Shares are not transferable without the Board's
prior written approval. SC and CBI agree to cause the Board not to consent to
any transfer of any Shares made other than in accordance with this Section 6.

         6.2 PREEMPTIVE RIGHTS. Except for the Shares subscribed under
Section 2.3 by the Holders, CBI and SC shall have preemptive rights to
purchase newly issued Shares pursuant to the applicable provisions of the
Japanese Commercial Code to subscribe for any Shares to be newly issued by
JVC to a Person or Persons other than CBI or SC so that CBI and SC shall
retain their respective Pro Rata Share in JVC ("Preemptive Rights"). As
required by Section 280.5 of the Japanese Commercial Code, JVC shall (i)
inform each Holder that JVC intends to issue new and additional Shares, (ii)
provide notice to each Holder individually that that Holders may exercise
their preemptive rights to the new issue ("Preemptive Rights Notice"), (iii)
each Preemptive Rights Notice shall give the exact date on which Holders'
preemptive rights will expire (JVC may select any date of expiration as along
as JVC provides notice of that date to the Holders), (iv) the Preemptive
Rights Notice shall be given to each Holder at least two weeks before the
expiration date of preemptive rights. If necessary for the purpose of this
Section 6.2, the Holders agree to vote their Shares, and shall cause their
Board nominees to vote, in favor of an increase in capital or the number of
authorized Shares.

7.       NONCOMPETITION

         7.1 COMPETITION IN DISTRIBUTION OF PRODUCTS. SC agrees that as long
as SC holds a JVC Interest, SC shall not engage, either directly or
indirectly, as a principal or for its own account or solely or jointly with
others, or as a shareholder in any corporation or joint stock association, in
any entity that sells, resells, or distributes any products in the life
sciences research market that materially competes with the sale of CBI's
Products (as defined in Section 1 of the Distribution and Marketing Agreement
attached in EXHIBIT B). This Section 7.1 shall not apply to substitutable or
similar products already being sold, resold or distributed by SC before the
Effective Date of this Agreement.

         7.2 RESEARCH USING CBI PRODUCTS FOR THIRD PARTIES. SC and its
Affiliates shall not use any of CBI's Products to conduct research and/or
development on behalf of any third party. JVC and its Affiliates shall not
use any of CBI's Products to conduct research and/or development on behalf of
any third party.

                                       -12-
<PAGE>

         7.3 OWNERSHIP OF INVENTIONS. Title to all inventions and all other
intellectual property derived from and relating to the use of CBI's Products
made solely by JVC employees or its agents or jointly by employees or the
agents of JVC and SC shall be owned by CBI.

         7.4 APPLICATIONS FOR RIGHTS. During the term of this Agreement,
neither SC nor its Affiliates and the JVC nor its Affiliates shall file any
patent, copyright or other similar applications with respect to any
intellectual property derived from or related to any of the Products (or
modifications thereof) or products which may compete herewith. If new
knowledge or experience is gained from the use of the Products, such
knowledge or experience shall be fully disclosed to CBI at the time of
discovery of the knowledge or experience. JVC shall grant CBI a
non-exclusive, royalty-free license with respect to improved or applied
inventions by the JVC derived from or related to any of the Products.

         7.5 ASSIGNMENT OF RIGHTS. JVC hereby assigns to CBI all of its
rights, title and interest it may otherwise hold (i) from the use of the
Products or modifications thereof, (ii) from any patent, copyright or other
similar applications with respect to any intellectual property derived from
or related to any of the Products or modifications thereof, or (iii) from any
other intellectual property rights relating to the Products or modifications
thereof. JVC shall, at the request of CBI, execute, and deliver or cause to
be delivered, all such consents, documents or further instruments of
assignment or transfer, and take or cause to be taken all such actions CBI
reasonably deems necessary or desirable in order for CBI to obtain the full
benefits of the assignment herein.

         7.6 INVALIDITY. If any provision contained in this Section 7 shall
for any reason be held invalid, illegal or unenforceable in any respect, such
invalidity, illegality of unenforceability shall not affect any other
provisions of this Section or this Agreement, but this Section and Agreement
shall be construed as if such invalid, illegal or unenforceable provision had
never been contained herein. It is the intention of CBI, SC and JVC that if
any of the restrictions or covenants contained herein is held to cover a
geographic area or to be for a length of time which is not permitted by
applicable law, or in any way construed to be too broad or to any extent
invalid, such provision shall not be construed to be null, void and of no
effect, but to the extent such provision would be valid or enforceable under
applicable law, a court of competent jurisdiction shall construe and
interpret or reform this Section 7 to provide for a covenant having the
maximum enforceable geographic area, time period and other provisions (not
greater than those contained herein) as shall be valid and enforceable under
such applicable law.

8.       REPRESENTATIONS

         8.1 CBI. CBI represents and warrants as follows to SC as of the date
of this Agreement and the date of the Closing:

                  (a) ORGANIZATION AND GOOD STANDING OF CBI. CBI is a
corporation duly organized, validly existing and in good standing under the
laws of the State of California and has the corporate power and authority to
engage in the business CBI is presently engaged in and to enter into this
Agreement and to perform its obligations hereunder.

                                       -13-
<PAGE>

                  (b) AUTHORIZATION. All corporate action on the part of CBI
and CBI's officers and directors necessary for the authorization, execution,
delivery and performance of this Agreement, the Distribution and Marketing
Agreement, and the Representative Directors Agreement has been taken. Each of
this Agreement and other agreements constitutes a valid, legally binding and
enforceable obligation of CBI.

                  (c) GOVERNMENT AND OTHER CONSENTS. Except for those
governmental consents or approvals contemplated by this Agreement, no
consent, authorization, license, permit, registration or approval of any
governmental or public body or authority is required in connection with CBI's
execution and delivery of this Agreement by CBI or with the performance by
CBI of its respective obligations hereunder.

                  (d) EFFECT OF AGREEMENT. CBI's execution and delivery of
this Agreement, performance of CBI's obligations hereunder and CBI's
consummation of the transactions contemplated hereby will not, (i) to CBI's
knowledge, violate any provision of any law, statute, rule or regulation to
which CBI is subject; (ii) violate any judgment, order, writ, injunction or
decree of any court applicable to CBI; (iii) to CBI's knowledge, have any
effect on the compliance of CBI with any laws, statutes, rules, regulations,
orders, decrees, licenses, permits or authorizations which would materially
and adversely affect CBI; (iv) to CBI's knowledge, result in the breach of,
or be in conflict with, any term, covenant, condition or provision of, or
affect the validity, enforceability and subsistence of any agreement, lease
or other commitment to which CBI is a party and which would materially and
adversely affect CBI; or (v) to CBI's knowledge, result in the creation or
imposition of any lien, pledge, mortgage, claim, charge, or encumbrance upon
any assets of CBI.

                  (e) BROKERS, FINDERS. CBI has not retained any person to
act on CBI's behalf, nor has any person contended that such person was so
retained, to assist CBI as CBI's broker, finder or agent in connection with
this joint venture.

                  (f) DISCLOSURE. No representation or warranty by CBI
contained in this Agreement and no writing, certificate, exhibit, list or
other instrument required to be furnished pursuant hereto contains or will
contain any untrue statement of a material fact or omits or will omit any
material fact necessary in order to make the statements and information
contained therein not misleading.

         8.2 SC. SC represents and warrants to CBI as follows as of the date
of this Agreement and the date of the Closing:

                  (a) ORGANIZATION AND GOOD STANDING OF SC. SC is a
corporation duly organized, validly existing and in good standing under the
laws of Japan and has the corporate power and authority to engage in the
business SC is presently engaged in and to enter into this Agreement and to
perform its obligations hereunder.

                  (b) AUTHORIZATION. All corporate action on the part of SC
and its officers and directors necessary for the authorization, execution,
delivery and performance of this Agreement, Distribution and Marketing
Agreement, and the Representative Directors Agreement has been taken.

                                       -14-
<PAGE>

Each of these Agreements and other agreements constitutes a valid, legally
binding and enforceable obligation of SC.

                  (c) GOVERNMENT AND OTHER CONSENTS. Except as to those
government consents or approvals contemplated by this Agreement, no consent,
authorization, license, permit, registration or approval of governmental or
public body or authority is required in connection with execution and
delivery of this Agreement by SC or with the performance by SC of any of its
respective obligations hereunder.

                  (d) EFFECT OF AGREEMENT. SC's execution and delivery of
this Agreement, performance of its obligations hereunder and SC's
consummation of the transactions contemplated hereby will not, (i) to SC's
knowledge, violate any provision of any law, statute, rule or regulation to
which SC is subject; (ii) violate any judgment, order, writ, injunction or
decree of any court applicable to SC; (iii) to SC's knowledge, have any
effect on the compliance of SC with any laws, statutes, rules, regulations,
orders, decrees, licenses, permits or authorizations which would materially
and adversely affect SC; (iv) to SC's knowledge, result in the breach of, or
be in conflict with, any term, covenant, condition or provision of, or affect
the validity, enforceability and subsistence of any agreement, lease or other
commitment to which SC is a party and which would materially and adversely
affect SC; or (v) to SC's knowledge, result in the creation or imposition of
any lien, pledge, mortgage, claim, charge, or encumbrance upon any assets of
SC.

                  (e) BROKERS, FINDERS. SC has not retained any person to act
on SC's behalf, nor has any person contended that such person was so
retained, to assist SC as SC's broker, finder or agent in connection with
this joint venture.

                  (f) DISCLOSURE. No representation or warranty by SC
contained in this Agreement and no writing, certificate, exhibit, list or
other instrument required to be furnished pursuant hereto contains or will
contain any untrue statement of a material fact or omits or will omit any
material fact necessary in order to make the statements and information
contained therein not misleading.

9.       CONDITIONS TO CLOSING

         9.1 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF SC. The obligations
of SC to purchase Shares under this Agreement are subject to satisfaction of
each of the following conditions at the Closing (unless waived by SC):

                  (a) REPRESENTATIONS AND WARRANTIES. The representations and
warranties of CBI contained in Section 5.1 shall be correct as of the
Closing, and CBI shall have delivered to SC a certificate of CBI, dated as of
the Closing Date, to this effect.

                  (b) COVENANTS. CBI shall have performed all covenants to be
performed by CBI under this Agreement and before the Closing, and CBI shall
have delivered to SC a certificate of CBI, dated as of the Closing Date, to
this effect.

                                       -15-
<PAGE>

                  (c) THIRD PARTY NOTIFICATIONS AND CONSENTS. Any government
notifications and consents required to be made or obtained prior to the
Closing shall have been made or obtained before the closing, and all required
waiting periods shall have expired.

                  (d) NO SUITS, PROCEEDINGS. No suit, action, investigation,
inquiry or proceeding by any person or by any governmental body, or other
legal or administrative proceeding shall have been instituted or threatened
which questions the validity or legality of the transactions contemplated
hereby.

                  (e) AGREEMENTS. The Distribution and Marketing Agreement as
attached in EXHIBIT B and Representative Director Agreement as attached in
EXHIBIT C have been executed.

         9.2 CONDITIONS PRECEDENT TO THE OBLIGATIONS OF CBI. The obligations
of CBI under this Agreement and to purchase Shares at the Closing are subject
to satisfaction of the following conditions at the Closing (unless waived by
CBI):

                  (a) REPRESENTATIONS AND WARRANTIES. The representation and
warranties of SC contained in Section 5.2 of this Agreement shall be true and
correct as of the Closing, and SC shall have delivered to CBI a certificate
of SC, dated as of the Closing Date, to this effect.

                  (b) COVENANTS. SC shall have performed all covenants to be
performed by SC under this Agreement and before the Closing, and SC shall
have delivered to CBI a certificate of SC, dated as of the Closing Date, to
this effect.

                  (c) THIRD PARTY NOTIFICATIONS AND CONSENTS. Any government
notifications and consents required to be made or obtained before the Closing
shall have been made or obtained before the Closing, and all required waiting
periods shall have expired.

                  (d) NO SUITS, PROCEEDINGS. No suit, action, investigation,
inquiry or proceeding by any person or by any governmental body, or other
legal or administrative proceeding shall have been instituted or threatened
which questions the validity or legality of the transactions contemplated
hereby.

                  (e) AGREEMENTS. The Distribution and Marketing Agreement as
attached in EXHIBIT B and Representative Director Agreement as attached in
EXHIBIT C have been executed.

         9.3 TIME AND PLACE OF CLOSING. The Closing shall occur upon the
execution of this Agreement by the Holders on December __, 1998 in Tokyo,
Japan, or at such time and place as CBI and SC may mutually agree.

         9.4 POST-CLOSING EVENTS.

                  (a) SC shall file the application for registration of
incorporation of JVC with the corporate registry office in the administrative
district where the head office of JVC is to be located.

                                       -16-
<PAGE>

                  (b) SC shall provide CBI with a reasonably itemized listing
of the out-of-pocket costs SC incurred in incorporating JVC and causing its
initial share issuances, which shall be reimbursed by the JVC within 30 days
after the application for registration of incorporation is approved.

                  (c) As soon as practicable after Closing, JVC shall issue
to CBI certificates evidencing the Shares purchased pursuant to Section 2.3
and record issuances of JVC Shares in JVC's shareholders register.

                  (d) Each Holder shall vote all Shares and voting Shares
held by the Holder to effect the provisions of this Agreement.

                  (e) JVC and CBI shall execute and deliver to each other the
Distribution and Marketing Agreement.

10.      TERM AND TERMINATION

         10.1         TERM. This Agreement shall continue in full force and
effect until terminated as provided herein under this Section 10.

         10.2         GROUNDS FOR TERMINATION.  This Agreement may terminate
only

                  (a) 10 years after the Effective Date of this Agreement; or

                  (b) at such time as only one Holder remains subject to this
Agreement; or

                  (c) the Closing does not occur by December 31, 1998.

         The respective obligations of CBI, SC and JVC pursuant to Sections
6, 7, 10, 11.1 and 11.15 shall survive a termination for any reason.

         10.3         TERMINATION UPON BANKRUPTCY OR INSOLVENCY OF A HOLDER.

                  (a) RIGHT TO TERMINATE. A Holder shall have the right to
notify the other Holder that this Agreement has terminated if any of the
following events occurs with respect to the other Holder after CBI exercises
its Buyout Option:

                           (i) Appointment of a custodian for all or
substantially all of the property of the other Holder.

                           (ii) The determination by a court or tribunal of
competent jurisdiction that the other Holder is insolvent.

                           (iii) The filing of a petition for liquidation
(and not for reorganization) in bankruptcy by the majority shareholder on its
own behalf or the filing of any such petition against the majority if the
proceeding is not dismissed or withdrawn within 60 days thereafter. The
majority shareholder shall not file for liquidation of the JVC without the
minority shareholder's consent.

                                       -17-
<PAGE>

                           (iv) An assignment of all or substantially all
assets by the other Holder for the benefit of its creditors.

                           (v) The dissolution or liquidation of the other
Holder other than in consequence of a merger, amalgamation or other corporate
reorganization to which it is a party.

                  (b)  NOTICE OF EVENT. If a Holder suffers any such event,
that Holder shall immediately notify the other Holder and JVC of the
occurrence of such event.

                  (c)  RIGHT TO PURCHASE. After notice of termination, the
Holders shall consult in good faith for 60 days concerning the disposition of
their respective interests in JVC and the future operations of JVC. If the
Holders do not sign a written agreement regarding such matters during such 60
days, then the Holder who gave notice of termination shall have the exclusive
option to purchase the JVC Interest of the other Holder.

                  10.4 Termination Upon Bankruptcy or Insolvency of JVC.

                  (a)  RIGHT TO TERMINATE. If any of the following events
("Liquidating Event") occurs to the JVC after CBI exercises its Buyout Option
and such event is not cured within 60 days following the event, the Holder of
majority Shares shall have the right to terminate this Agreement with the
consent of the Holder of minority Shares:

                           (i) JVC becomes insolvent or unable to pay any or
all of its debts as they mature or ceases to pay any or all of its debts as
they mature in the ordinary course of business.

                           (ii) Any application or petition is submitted, by
or for JVC, for commencement of proceedings of bankruptcy, composition or
other similar proceedings under the applicable law.

                  (b)  RIGHT TO DISSOLVE. After the occurrence of a
Liquidating Event, the Holders shall consult in good faith for 60 days
concerning the disposition of their respective interests in JVC and the
future operations of JVC. If the Holders do not sign a written agreement
regarding such matters during such 60-day period, then CBI shall have the
option to cause liquidation or dissolution of JVC.

                  (c)  Right to Purchase or Sell

         If CBI decides to liquidate or dissolve the JVC after satisfying
Sections 10.4(a) and 10.4(b) above, CBI shall give notice to SC ("Liquidation
Notice"), and the following procedure shall apply:

                  (i)  SC shall provide irrevocable notice to CBI within 30
days after Liquidation Notice that SC desires to have the Fair Market Value
("FMV") of its JVC Shares determined pursuant to Section 10.8;

                  (ii) determination of FMV shall assume that JVC continues
to operate so that JVC's liquidation or dissolution does not give effect to
any decrease in FMV of JVC Shares;

                                       -18-
<PAGE>

                  (iii) within 5 days after FMV of JVC Shares is determined,
SC shall give irrevocable notice whether to buy or sell its JVC Shares
("Buy-Sell Notice");

                  (iv) the closing of the purchase or sale of SC's Shares
shall occur within 30 days after SC gives the Buy-Sell Notice, and payment
shall be made in cash;

                  (v) during the procedure in this Section 10.4(c), CBI or
JVC shall not take any action to cause the liquidation or dissolution of JVC.

         10.5         TERMINATION UPON MATERIAL BREACH.

                  (a) RIGHT TO TERMINATE. A Holder shall have the right to
notify the other Holder and JVC that this Agreement has terminated if the
other Holder commits a Material Breach (as defined below) of this Agreement.

                  (b) DEFINITION OF MATERIAL BREACH. The commission of any of
the following acts by a Holder, which is not cured within 60 days following
notice thereof to the breaching Holder by the other Holder or JVC, shall
constitute a Material Breach of this Agreement by such Holder:

                           (i) As to SC (or its Affiliates, if applicable)
the material failure by SC, or such Affiliates, to fully comply with its
obligations under this Agreement.

                           (ii) As to CBI (or its Affiliates, if applicable)
the material failure by CBI, or such Affiliates, to fully comply with its
obligations under this Agreement.

                  (c) RIGHT TO PURCHASE OR TO SELL. After notice of
termination, the Holders shall consult in good faith for 60 days concerning
the disposition of their respective interests in JVC and the future
operations of JVC. If the Holders do not resolve such matters in writing
within such 60 days, and SC is the breaching Holder, then for an additional
60 days CBI shall have an exclusive option to purchase SC's JVC Interest
pursuant to Section 10.8, provided that CBI may offset against the purchase
price for SC's JVC Interest the amount of damages sustained by JVC and CBI as
a result of such Material Breach. If the Holders do not resolve such matters
in writing within such 60 days, and CBI is the breaching Holder, then for an
additional 60 days SC shall have the exclusive option to purchase CBI's JVC
Interest pursuant to Section 10.8, provided that SC may offset against the
purchase price for CBI's JVC Interest the amount of damages sustained by JVC
and SC as a result of such Material Breach.

                  (d) REMEDIES NOT AFFECTED. The foregoing shall not limit
the ability of JVC or any Holder to seek such legal and equitable remedies
(including damages not fully offset by the reduction in purchase price)
related to a Material Breach by a Holder or the failure of a Holder to
perform any other duty or obligation.

         10.6 TERMINATION UPON GOVERNMENTAL ALTERATION OR MODIFICATION.

                  (a) RIGHT TO OBJECT. If at any time any government or
agency having jurisdiction over JVC, CBI, or SC should require, directly or
indirectly, any alteration or

                                       -19-
<PAGE>

modification of any term or condition of this Agreement, the Distribution and
Marketing Agreement, or of the performance by the Holders under such
agreements in a manner which has a material adverse effect on any Holder or
on the operations or financial condition or prospects of JVC, then the Holder
which suffers from such alteration or modification shall have the right to
notify the other Holder of its objection to such alteration or modification.

                  (b) RIGHT TO TERMINATE. If a Holder gives such a notice,
then (i) the Holders shall negotiate in good faith a mutually satisfactory
resolution of such objection for 60 days; (ii) if no resolution results, the
President of CBI and the President of SC shall meet personally and negotiate
in good faith to resolve such objection within 60 days after the initial 60
day period. If such mutual consultation does not resolve such objection, then
the suffering Holder shall have the right to notify the other Holders and the
JVC that this Agreement has terminated and to cause dissolution of JVC. Upon
such dissolution each Holder and JVC shall take all actions (including voting
of the Shares) required to dissolve and liquidate JVC in accordance with
applicable laws and regulations.

                  (c) LIMITED LIABILITY. The Holder which terminates this
Agreement shall not incur any liability to the other Holders or to the JVC
for any alleged default in the performance of this Agreement arising from the
exercise of its termination rights under this Section 10.6.

         10.7 CONTINUED RIGHT TO PURCHASE. If a Holder terminates this
Agreement pursuant to this Section 10, but does not have the necessary number
of Shares to cause liquidation or dissolution of JVC and does not purchase
the other Holder's entire JVC Interest, then the Shares held by the other
Holder shall continue to be subject to any right of purchase held by the
Holder which terminated this Agreement.

         10.8         PURCHASE PROCEDURES.

                  (a) The purchase price for the Shares to be sold pursuant
to this Section 10 shall be the "Fair Market Value" of such Shares.

                  (b) "Fair Market Value" per share shall be determined as
follows:

                           (i) If the Shares are publicly traded on a
national securities exchange or the Japanese OTC market, the value shall be
deemed to be the average of the closing prices of the Shares on such exchange
or market, as the case may be, over the 30-day period ending 3 business days
prior to the closing of the purchase of the Shares.

                           (ii) If there is no active public market for the
Shares, the value shall be the fair market value thereof as determined by
good faith negotiation between the selling Holder or Holders ("Seller") and
the purchasing Holder or Holders ("Purchaser"). If such negotiation fails to
determine the fair market value within 90 days after the date of the notice
of termination, the fair market value shall be determined as follows:

                                    (1) Seller and Purchaser shall each
retain at its expense an investment bank expert in the life sciences research
market. If Seller or Purchaser does not select an investment bank within 30
days after the end of the 90-day good faith negotiation period referred to

                                       -20-
<PAGE>

in subsection (ii) above, such Holder or Holders shall not be entitled to
retain an investment bank and shall present whatever materials it has
available by the deadline regarding the valuation of JVC.

                                    (2) Subject to execution of customary
confidentiality agreements by the investment banks, JVC shall provide or
cause to be provided to each investment bank all material information,
including any material changes in such information, reasonably necessary to
value JVC or reasonably requested by the investment banks.

                                    (3) During the 60-day period after both
Seller and Purchaser have selected an investment bank, or the end of the
30-day period in Section 10.8(b)(ii)(1) above if Seller and/or Purchaser does
not select an investment bank (the "Negotiation Period"), Seller, Purchaser
and their respective investment banks shall meet on at least two occasions to
present their respective views on valuation and shall negotiate in good faith
to reach a written agreement on the fair market value.

                                    (4) If the fair market value has not been
agreed to in writing by the end of the Negotiation Period, Seller and
Purchaser shall each submit a final valuation proposal with a supporting
analysis to the other Holder or Holders and to the "Arbitrator" within 10
days after the end of the Negotiation Period. The "Arbitrator" shall be a
Person with expertise in valuing companies in the life sciences research
market, shall not have a material business relationship with CBI, SC or JVC
and shall be reasonably acceptable to both Seller and Purchaser.

                                    (5) If Seller or Purchaser does not
submit in a timely manner a final valuation proposal, then the valuation
proposal of the other Holder or Holders shall be used to establish the fair
market value. If the final proposals differ by less than 15%, then the
average of the proposals shall be the fair market value. If the final
proposals differ by 15% or more, then the Arbitrator shall choose one or the
other proposal. The Arbitrator's determination shall be final and binding on
both Seller and Purchase; provided, however, that the Arbitrator must select
one of the final valuation proposals as submitted.

                  (c) Each Holder purchasing Shares under this Section 10.8
shall pay in cash or other immediately available funds the aggregate purchase
price for the Shares to be sold to such Holder upon receipt of the
certificate or certificates for the Shares to be sold to such Holder.

                  (d) When Holders have the right to purchase their pro rata
share of another Holder's Shares pursuant to this Section 10.8 and not all of
those Holders exercise their purchase right, the Holders exercising their
purchase right shall also have the right to purchase the pro rata share of
the Shares of the Holders not exercising their purchase right (the "Remaining
Shares"). If more than one Holder elects to exercise its purchase right as to
the Remaining Shares, each Holder who wishes to purchase the Remaining Shares
shall be entitled to purchase that portion of the Remaining Shares as the
total number of Shares then owned by such Holder bears to the total number of
Shares then owned by all Holders who wish to purchase the Remaining Shares.

         10.9 CONTINUATION OF BUSINESS. During any period in which a Holder
has the right to purchase or is purchasing the JVC Interest of the other
Holder pursuant to this Section 10:

                                       -21-
<PAGE>

                  (a) JVC shall continue its business in the ordinary course.
CBI, SC and JVC shall use their best efforts to maintain and preserve the
business of JVC pending the consummation of such purchase.

                  (b) Unless the Holders otherwise agree in writing, no other
agreement between the Holders, between any two of the Parties or among the
Parties, and other related agreements shall be amended or terminated.

                  (c) The Holders shall negotiate in good faith an agreement
providing that employees of such selling Holder working full-time for JVC
shall be made available full-time to JVC for such period as is reasonably
required up to 6 months to effect an orderly transition to sole ownership by
one Holder, and each Holder shall use its best efforts to make all such
employees available on this basis.

                  (d) If CBI purchases SC's JVC Interest, then until one year
after the purchase has been completed SC shall not assign to its employees
who have worked at JVC, or to any employees of JVC who become employees of
SC, responsibilities which relate to the development, distribution or
marketing of products competitive with the Products (as defined in Section 1
of the Distribution and Marketing Agreement attached in EXHIBIT B)
distributed by JVC or which JVC was preparing to distribute, at the time of
the purchase.

11.      GENERAL PROVISIONS

         11.1 CONFIDENTIALITY.

                  (a) Each Party to this Agreement acknowledges and agrees
that certain information it receives from any of the other Parties
constitutes the confidential and proprietary trade secrets of the disclosing
Party, and that the receiving Party's protection thereof is essential to this
Agreement and a condition of the receiving Party's use and possession
thereof. Each Party shall retain in strict confidence any and all such
confidential and proprietary information marked by the disclosing Party as
confidential (collectively, "Confidential Information") and use such
Confidential Information only as expressly authorized by the Holders. A Party
will under no circumstances distribute or in any way disseminate Confidential
Information to third parties without the prior written permission of the
Holders.

                  (b) Notwithstanding the above, the receiving Party shall
have no liability to the disclosing Party with regard to Confidential
Information which:

                           (i) was generally known and available in the
public domain at the time it was disclosed or becomes generally known and
available in the public domain through no fault of the receiving Party;

                           (ii) was known to the receiving Party at the time
of disclosure as shown by the files of the receiving Holder in existence at
the time of disclosure;

                           (iii) is disclosed with the prior written approval
of the disclosing Party;

                                       -22-
<PAGE>

                           (iv) was independently developed by the receiving
Party (or by its employees or agents who have not been exposed to such
Confidential Information) without any use of Confidential Information or use
of CBI Products;

                           (v) becomes known to the receiving Party from a
source other than the disclosing Party without breach of this Agreement or
the Distribution and Marketing Agreement attached in EXHIBIT B by the
receiving Party and otherwise not in violation of the disclosing Party's
rights; or

                           (vi) is disclosed pursuant to the order or
requirement of a court, administrative agency, or other governmental body;
provided, that the receiving Party shall provide prompt, advanced notice
thereof to enable the disclosing Party to seek a protective order or
otherwise prevent such disclosure.

                  (c) Each Party will enter into a confidentiality agreement
similar to CBI's form confidentiality agreement with each employee who is
given access to the Confidential Information of any of the Parties which
incorporates the protections and restrictions substantially as set forth
herein.

                  (d) Each Party agrees to notify the other Holders in the
event of any breach of its security under conditions in which it would appear
that Confidential Information was prejudiced or exposed to loss. Each Party
shall, upon request of the disclosing Party, take all other reasonable steps
necessary to recover any compromised Confidential Information disclosed to or
placed in its possession by virtue of this Agreement. The cost of taking such
steps shall be borne solely by the receiving Party.

                  (e) Each Party acknowledges that any breach of any of its
obligations under this Section 11.1 is likely to cause or threaten
irreparable harm to the other Parties, and accordingly, each Party agrees
that in such event the disclosing Party shall be entitled to equitable relief
to protect its interests, including but not limited to preliminary and
permanent injunctive relief, as well as money damages.

         11.2 ARBITRATION; FORUM.

                  (a) ARBITRATION. All other disputes, controversies or
claims arising out of or relating to this Agreement, or the breach,
termination or validity thereof, shall be resolved by one arbitrator under
the Rules of International Chamber of Commerce which rules are hereby
incorporated by reference into this Section 11.2. The place of arbitration
shall be Honolulu, Hawaii. The language to be used in the arbitration
proceedings shall be English. The arbitrator may be of any nationality, but
must have knowledge of the life sciences research market in Japan and in the
United States. The arbitral award shall be rendered in writing and state the
reasons for the award. Judgment on any award may be entered by any court of
competent jurisdiction or application may be made to such a court for
judicial acceptance of the award and any appropriate order including
enforcement.

                                       -23-
<PAGE>

                  (b) EXPENSES OF LITIGATION. In case of litigation arising
out of this Agreement, the prevailing Party shall be entitled to recover its
reasonable attorneys' fees and expenses from either of the other Parties. In
case of arbitration between Holders, the arbitrators shall award reasonable
attorneys' fees and expenses to either Holder in such manner and to such
extent as the arbitrators deem equitable.

                  (c) OTHER RELIEF. Notwithstanding the foregoing, the
Holders may apply to any court of competent jurisdiction for a temporary
restraining order, preliminary injunction, or other interim or conservatory
relief, as necessary, without breach of this section, and without any
abridgement of the powers of the arbitrator.

         11.3 FORCE MAJEURE. If the performance of this Agreement or any
obligations hereunder is prevented, restricted or interfered with by reason
of fire or other casualty or accident, strikes or labor disputes, war or
other violence, any law, order, proclamation, regulations, ordinance, demand
or requirement of any government agency, or any other act or condition beyond
the reasonable control of the Parties to this Agreement, any Party so
affected upon giving prompt notice to the other Parties shall be excused from
such performance during such prevention, restriction or interference.

         11.4 LAW TO GOVERN. This Agreement shall be governed by the laws of
Japan.

         11.5 PUBLICITY. Prior to issuing any reports, statements, press
releases or other disclosures to third parties regarding this Agreement or
the transactions contemplated herein, the Holders shall exchange copies of
such documents and shall consult with each other Holder regarding their
content. Except as otherwise required by law, neither Holder nor the JVC
shall issue any such disclosure without the prior approval of the Holders.

         11.6 NOTICES AND OTHER COMMUNICATIONS. Every notice by any of the
Parties herein shall be in writing and delivered either by personal delivery,
or by Express Mail or any similar overnight courier service, or by registered
or certified mail, postage prepaid, or by fax or e-mail, addressed to the
Party for whom intended at its address set forth above, or at such other
address as the intended recipient previously shall have designated by written
notice to the other Party. All notices delivered in person shall be deemed to
have been delivered to and received by the addressee and shall be effective
on the date of personal delivery. All notices delivered by Express Mail or
any other similar overnight courier service shall be effective upon receipt.
All notices delivered by registered or certified mail, or by fax or e-mail,
shall be effective upon receipt.

         11.7 COUNTERPARTS. This Agreement may be executed in any number of
English language counterparts or duplicate originals, and each such
counterpart or duplicate original shall constitute an original instrument,
but all such separate counterparts or duplicate originals shall constitute
one and the same instrument.

         11.8 WRITTEN AGREEMENT TO GOVERN. This Agreement sets forth the
entire understanding and supersede all prior and contemporaneous agreements
and discussions between the Holders relating to the specific subject matter
contained herein or therein, and neither Holder shall be bound by any
definition, condition, representation, warranty, covenant or provision other
than as

                                       -24-
<PAGE>

expressly stated in or contemplated herein or therein or as subsequently
shall be set forth in writing and executed by a duly authorized
representative or agent of the Holder to be bound thereby.

         11.9 NO WAIVER OF RIGHTS. All waivers hereunder must be made in
writing, and failure at any time to require any Party's performance of any
obligation under this Agreement shall not affect the right subsequently to
require performance of that obligation. No waiver of any breach of any
provision of this Agreement shall be construed as a waiver of any continuing
or succeeding breach of such provision or a waiver or modification of such
provision.

         11.10 SEVERABILITY. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Agreement should be
prohibited or invalid under applicable law, (including, without limitation,
objections by the Japanese Fair Trade Commission) such provisions shall be
ineffective to the extent of such prohibition or invalidity without
invalidating the remainder of such provision or the remaining provisions of
this Agreement. In such event, the Holders agree to negotiate, in good faith,
a valid, legal and enforceable substitute provision which most nearly effects
the Holders' intent in entering into this Agreement.

         11.11 SUBJECT HEADINGS. The subject headings of the Sections of this
Agreement are included for the purposes of convenience only, and shall not
affect the construction or interpretations of any of its provisions.

         11.12 FURTHER ASSURANCES. The Parties shall each perform such acts,
execute and deliver such instruments and documents, and do all such other
things as may be reasonably necessary to accomplish the transactions
contemplated in this Agreement.

         11.13 EXPENSES AND FINDER'S FEES. The Holders shall each bear their
own costs and expenses (including attorneys' fees) incurred in connection
with the negotiation and preparation of this Agreement and the consummation
of the transactions contemplated hereby. Each Holder shall indemnify the
other Holder against any claim for brokerage or finder's fees arising out of
the transactions contemplated herein by any person claiming to have been
engaged by the indemnifying Holder based upon any action or communication, or
any alleged action or communication, by the indemnifying Holder or any of its
officers or employees. Pursuant to Section 9.4(b), JVC shall bear the costs
of incorporation and issuance of the initial Shares.

         11.14 RELATIONSHIP AMONG PARTIES. Each of CBI, SC and JVC will in
all matters relating to this Agreement be and act as an independent
contractor. None of the Parties will represent that it has any authority to
assume or create any obligation, express or implied, on behalf of any of the
other Parties, or to represent any of the other Parties as agent, employee,
or in any other capacity.

         11.15 CONFIDENTIALITY OF AGREEMENT. The Parties shall hold in
confidence and not disclose to any third party, without the prior written
consent of both Holders, the terms and conditions of the Agreement, provided
that each Party may disclose the terms and conditions of this Agreement

                                       -25-
<PAGE>

                  (a) as required by any court or other governmental body;

                  (b) as otherwise required by law;

                  (c) to legal counsel of each of the Parties;

                  (d) in confidence, to accountants, banks and financing
sources and their advisors;

                  (e) in connection with the enforcement of this Agreement or
rights under this Agreement; or

                  (f) in confidence, in connection with a merger or
acquisition or proposed merger or acquisition, or the like.

       11.16 LANGUAGE. This Agreement is in the English language only, which
language shall be controlling in all respects, and all versions hereof in any
other language shall be for accommodation only and shall not be binding upon
all Parties hereto. All communications and notices to be made or given
between Holders pursuant to this Agreement shall be in the English language.

       11.17 ASSIGNMENT. This Agreement shall inure to benefit of, and shall
be binding upon, the Parties and their respective successors and assigns. No
Party may assign or delegate this Agreement or any of its rights or duties
under this Agreement without the prior written consent of both Holders except
as expressly set forth herein or to a Person or entity into which it has
merged or which has otherwise succeeded to all or substantially all of the
business and assets of the assignor ("Successor"), and which has assumed in
writing or by operation of law the assignor's obligations under this
Agreement.

       11.18          FOREIGN CORRUPT PRACTICES ACT.

                  (a) All of the Parties to this Agreement acknowledge that
the laws, rules, regulations and decrees of the various jurisdictions in
which JVC conducts its business, and of the United States of America, shall
apply to the actions of JVC. The Parties recognize that the United States
Foreign Corrupt Practices Act of 1977 (the "Act") may be applicable to JVC's
activities. The Parties recognize that the Act prohibits the payment or
giving of anything of value either directly or indirectly to a government
official for the purpose of influencing an act or decision in his or her
official capacity, or for the purpose of inducing him to use his influence
with his government to assist a company in obtaining or retaining business
for or with, or directing business to, any Person.

                  (b) The Parties represent and warrant that they are
familiar with the Act and its purposes, and that none of the Parties nor
their owners, officers, directors, partners, principals, employees, staff
members, or agents are officials, officers or representatives of any
government or political party or candidates for political office. The Parties
shall ensure that no part of JVC's capital or other funds will be accepted or
used by JVC for any purpose, nor will it take any action, which

                                      -26-
<PAGE>

would constitute a violation of any law of the various jurisdictions in which
it conducts business or of the United States of America, including the Act.

                  (c) Should any of the Parties ever receive, directly or
indirectly, a request which any of them believes will or might constitute a
violation of the Act, it shall immediately notify CBI.

                                       -27-
<PAGE>

         IN WITNESS WHEREOF, the undersigned are duly authorized to execute
this Agreement on behalf of CBI and SC as applicable.

CIPHERGEN BIOSYSTEMS, INC. ("CBI")            SUMITOMO CORPORATION ("SC")

By:                                           By:
   ----------------------------------            -------------------------------

Title:                                        Title:
      -------------------------------               ----------------------------

Dated                                         Dated:
      -------------------------------               ----------------------------

JVC agrees to be bound by all provisions of this Agreement applicable to it.

CIPHERGEN BIOSYSTEMS K.K. ("JVC")

By:
   ----------------------------------

Title:
      -------------------------------

Dated
      -------------------------------

                                       -28-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]